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Ceftolozane-tazobactam has potent activity against Pseudomonas aeruginosa, a pathogen associated with cystic fibrosis (CF)
acute pulmonary exacerbations (APE). Due to the rapid elimination of many antibiotics, CF patients frequently have altered
pharmacokinetics. In this multicenter, open-label study, we described the population pharmacokinetics and safety of ceftolo-
zane-tazobactam at 3 g every 8 h (q8h) in 20 adult CF patients admitted with APE. Population pharmacokinetics were deter-
mined using the nonparametric adaptive grid program in Pmetrics for R. A 5,000-patient Monte Carlo simulation was per-
formed to determine the probability of target attainment (PTA) for the ceftolozane component at 1.5 g and 3 g of ceftolozane-
tazobactam q8h across a range of MICs using a primary threshold exposure of 60% free time above theMIC (fT>MIC). In these
20 adult CF patients, ceftolozane and tazobactam concentration data were best described by 2-compartment models, and cef-
tolozane clearance (CL) was significantly correlated with creatinine clearance (r 0.71, P< 0.001). These data suggest that cef-
tolozane and tazobactam clearance estimates in CF patients are similar to those in adults without CF (ceftolozane CF CL, 4.76
1.13 liter/h; tazobactam CF CL, 20.51 4.41 liter/h). However, estimates of the volume of the central compartment (Vc) were
lower than those for adults without CF (ceftolozane CF Vc, 7.51 2.05 liters; tazobactam CF Vc, 7.85 2.66 liters). Using a
threshold of 60% fT>MIC, ceftolozane-tazobactam regimens of 1.5 g and 3 g q8h should achieve PTAs of>90% at MICs up to 4
and 8g/ml, respectively. Ceftolozane-tazobactam at 3 g q8h was well tolerated. These observations support additional studies
of ceftolozane-tazobactam for Pseudomonas aeruginosa APE in CF patients. (This study has been registered at ClinicalTrials.gov
under identifier NCT02421120.)
Cystic fibrosis (CF) is an autosomal recessive genetic disorderthat affectsmultiple organ systems (1). Nearly 1,000 new cases
of CF are diagnosed annually in the United States, and more than
75% of these diagnoses are made by the age of 2 (2). Understand-
ing the importance of augmenting airway clearance, aggressively
treating infection, and correcting nutrition deficits have collec-
tively increased the median survival from 31 years in 2002 to 41
years in 2013, with approximately half of CF patients being 18
years or older (1, 2). Lungs are the most prominent affected or-
gans, and 85% of CFmortality is attributed to lung disease (3). CF
lung disease begins with inflammation of the pulmonary tissues
along with impaired airway mucociliary clearance, which conse-
quently results in chronic infection of the airways due to impaired
bacterial clearance. Lung function in CF progressively declines
with the occurrence of acute episodes of pulmonary exacerbation
caused by the organisms chronically occupying the CF airway (3).
Common organisms that inhabit the lungs of adult CF patients
include Pseudomonas aeruginosa and Staphylococcus aureus, in-
cluding drug-resistant strains (2). High rates of antimicrobial re-
sistance are reported within these organisms as a consequence of
repeated exposures to multiple antibiotic courses for the manage-
ment of chronic infections (2, 4). Furthermore, some resistant
phenotypes challenge antibiotic therapy through the formation of
biofilms (production of mucoid alginate by the bacteria to im-
prove survival), collectively making it difficult to eradicate a
pathogen from the CF lung (4). Despite these challenges, intrave-
nous antibiotics with antipseudomonal activity continue to be the
mainstay of treatment for acute pulmonary exacerbations in adult
CF patients; however, new agents are needed to address the devel-
opment of resistance within these difficult-to-treat pathogens.
Ceftolozane is a novel, broad-spectrum cephalosporin antibi-
otic approved for the treatment of complicated urinary tract and
complicated intra-abdominal infections (5). Currently, the anti-
biotic is also being studied for the treatment of ventilated nosoco-
mial pneumonia (ClinicalTrials registration no. NCT02070757).
Compared with other currently available cephalosporins, ceftolo-
zane is intrinsically more stable against the multiple resistance
mechanisms employed by P. aeruginosa, such as AmpC -lacta-
mase production and efflux (6–8).When ceftolozane is combined
with tazobactam, an older -lactamase inhibitor, the antimicro-
bial coverage of ceftolozane-tazobactam (Zerbaxa; Merck & Co.,
Inc.) broadens to include Gram-negative organisms producing
some-lactamases, including certain extended-spectrum-lacta-
mases. Given the potent activity of ceftolozane-tazobactam
against P. aeruginosa, including multidrug resistant isolates from
CF patients, this antibiotic could play a significant role in the
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treatment of CF acute pulmonary exacerbations. However, there
is established evidence that patients with CF may have altered
pharmacokinetics comparedwith those of non-CFpatients (4). As
a result, it would be prudent to understand the pharmacokinetics
of ceftolozane in adult CF patients in order to select the appropri-
ate dosing regimen in this special population, which might differ
from the dosing used to treat infections in non-CF patients.
MATERIALS AND METHODS
Study design and participants. This study was a prospective, multi-
center, open-label pharmacokinetic trial (ClinicalTrials registration no.
NCT02421120) of ceftolozane-tazobactam in 20 CF adults hospitalized
for the treatment of an acute pulmonary exacerbation requiring intrave-
nous antibiotic therapy. The study was reviewed and approved by the
institutional review boards of all participating centers (Hartford Hospital
IRB HHC-2015-0107, University of North Carolina IRB 15-1307, Drexel
[St. Christopher’s Hospital for Children] IRB 1506003732, and Indiana
University IRB 1504405675), and informed consent was required of all
participants. Inclusion criteria required that each participant was 18 years
of age or older, had documented CF, and was hospitalized for an acute
pulmonary exacerbation that required treatment with intravenous anti-
biotics as per their treating CF physician. If female, participants had to be
nonpregnant and nonlactating. Participants were excluded if they had any
of the following: history of any moderate or severe hypersensitivity or
allergic reaction to any-lactam antibiotic; prior (within 24 h of receiving
the first dose of the study drug) or concomitant receipt of cefepime (the
internal standard for the assay), piperacillin-tazobactam, or any anionic
organic acids that are actively secreted through the renal tubule (i.e., pro-
benecid, furosemide, thiazide diuretics, and angiotensin-converting en-
zyme [ACE] inhibitors); history of a lung transplant at any time in the past
or any other organ transplantation within the last 6 months; moderate to
severe renal dysfunction, defined as a creatinine clearance (CLCR) of50
ml/min (as calculated by the Cockcroft-Gault equation using actual body
weight), or requirement for continuous renal replacement therapy or he-
modialysis; a hemoglobin level of less than 8 g/dl at baseline; any rapidly
progressing disease or immediately life-threatening illness (defined as im-
minent deathwithin 48 h in the opinion of the investigator); or planned or
prior participation in any other interventional drug study within 30 days.
Antibiotic administration. Participants received 4 to 6 doses of 3 g
ceftolozane-tazobactam every 8 h (q8h) with each dose infused as a 60-
min infusion, in addition to their standard antibiotic therapy. Commer-
cially available prepackaged preparations of 1.5 g (lot SP1334-A; expira-
tion date, April 2016) ceftolozane-tazobactam (Zerbaxa; Merck & Co.,
Inc., Kenilworth, NJ) were supplied by the manufacturer and stored ac-
cording to prescribing recommendations. For each dose, two vials of cef-
tolozane-tazobactam (1,000 mg/500 mg/vial) were reconstituted with 10
ml of 0.9% sodium chloride for injection or sterile water for injection. The
entire volume (11 ml) of each reconstituted vial was added to an infu-
sion bag containing 80 ml of 0.9% sodium chloride for injection, for a
total volume of approximately 102 ml. All doses were stored in a refriger-
ator (2°C to 8°C) until administration within 24 h.
Ceftolozane-tazobactam concentration determination. Blood sam-
ples were collected no earlier than after the third dose of ceftolozane-
tazobactam. Six samples per participant were collected at the following
time points: 0 h (immediately before the start of the final dose) and 0 to 5
min, 15 to 30min, 60 to 120min, 180 to 240min, and 360 to 420min after
the end of the infusion of the final dose. The exact times of sample collec-
tion were recorded for use in the pharmacokinetic analyses. All blood
samples were placed on ice for no longer than 5min and then immediately
centrifuged at 4,000  g for 15 min to collect the separated serum. The
serum was divided equally into three cryovials for storage at80°C until
ceftolozane and tazobactam concentrations were determined at the Cen-
ter for Anti-Infective Research and Development (Hartford, CT, USA).
Ceftolozane and tazobactam concentrations in plasma were assessed us-
ing a validated high-performance liquid chromatography (HPLC) proce-
dure determined using a previously published assay (9). The lower limit of
quantification of the assay was 0.4 g/ml for both analytes. For ceftolo-
zane, the mean interday coefficients of variation for high (40 g/ml) and
low (0.6 g/ml) check samples were 4.6% and 5.4%, respectively. The
mean intraday coefficients of variation were 3.2% and 7.4%, respectively.
For tazobactam, the mean interday coefficients of variation for high (40
g/ml) and low (0.6 g/ml) check samples were 4.8% and 5.9%, respec-
tively. The mean intraday coefficients of variation were 2.7% and 3.2%,
respectively.
Pharmacokinetic analyses. Concentration data for both ceftolozane
and tazobactam were modeled separately using the nonparametric adap-
tive grid program (NPAG) in Pmetrics for R (Laboratory of Applied Phar-
macokinetics and Bioinformatics, Los Angeles, CA) (10). One- and two-
compartment models were differentiated based on visual fit and the
Akaike information criterion (AIC) (11). A multiplicative assay variance
model was determined by fitting a polynomial to the plot of the interday
assay standard deviation (SD) versus the measured ceftolozane and tazo-
bactam concentrations, generating the formulas SD  	  (0.0039 

0.0469C) and SD	 (0.0425
 0.0391 T) where C is ceftolozane
concentration, T is tazobactam concentration, and 	 represents all envi-
ronmental variability excluding the assay. Separate estimates for 	 were
determined for ceftolozane and tazobactammodels. Once the base model
was established for ceftolozane, linear regression (Sigma Plot version 12.5;
Systat, Chicago, IL, USA) was used to characterize the relationship be-
tween clearance (CL) and volume of distribution parameters and partic-
ipant covariates (age [years], height [cm], weight [kg], serum creatinine
[mg/dl], creatinine clearance [CLCR] [ml/min]) as estimated by the Cock-
croft-Gault equation using actual body weight, body mass index [BMI]
[kg/m2], fat free mass [kg] [12], and lean body weight [kg] [13]). Covari-
ates were analyzed as ratios and by allometric scaling. Statistically signifi-
cant covariates were then incorporated into the population model and
tested for superiority by the log-likelihood ratio test. A covariate model
was not developed for tazobactam, since it contributes little to the micro-
biological activity of ceftolozane against P. aeruginosa.
Monte Carlo simulation. A 5,000-patient Monte Carlo simulation
(Crystal Ball; Oracle Corporation, Redwood Shores, CA) was conducted
for the ceftolozane component of the ceftolozane-tazobactam 1.5-g and
3-g q8h dosage regimens with each dose infused over 60 min. Only cef-
tolozanewas simulated due to its antipseudomonal activity. To determine
the covariance relationship between CLCR and all pharmacokinetic pa-
rameter estimates, Pmetrics was utilized to recreate the covariance matrix
while incorporating this variable. The mean, standard deviation, and co-
variance matrix for all pharmacokinetic parameters and CLCR were in-
serted into Crystal Ball to simulate an adult CF patient population that
was similar to the 20 participants enrolled. All pharmacokinetic parame-
ter estimates were assumed to follow log-Gaussian distributions, and the
CLCR distribution followed aGaussian shape and range that replicated the
distribution for the 20 participants (mean, 117.7ml/min; range, 62 to 197
ml/min). Concentrations were simulated at 15-min intervals for 7 doses.
The probability of pharmacodynamic target attainment (PTA) was as-
sessed over a range of MICs between 0.25 and 64 g/ml in doubling
dilutions. A protein binding estimate of 20% was used to correct total
ceftolozane concentrations to unbound drug (14). The pharmacody-
namic indices targeted included 39% free time above theMIC (fTMIC),
an exposure which demonstrated a 1-log kill against P. aeruginosa in a
murine thigh infection model (15), 60% fTMIC, an exposure com-
monly predictive of cephalosporinmicrobiological success in pneumonia
and CFU reduction against Gram-negative bacteria (16–19), and 100%
fTMIC as the maximal achievable fT[mt]MIC threshold for the dosing
interval. A PTA of90% was considered optimal.
Safety and tolerability. The safety and tolerability of ceftolozane-ta-
zobactam at 3 g q8h were assessed throughout the treatment course until
completion of the final blood sample. Safety was determined by assess-
ment of adverse events reported by the participant or medical provider
and any clinically significant changes in laboratory values (chemistry, he-
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matology, and liver function tests) between the start and completion of
therapy.
RESULTS
Participants.Twenty-one adult CF patients were enrolled, and 20
completed the study. Demographic and clinical characteristics for
the 20 participants are provided in Table 1. The bacteria isolated
included P. aeruginosa (n  14/20, 70%), S. aureus (n  11/20,
55%; 8/11 [73%] were methicillin-resistant S. aureus [MRSA]),
Escherichia coli (n 2/20, 10%),Achromobacter xylosoxidans (n
1/20, 5%), and Burkholderia cepacia (n 1/20, 5%). One partici-
pant had no bacteria isolated at baseline, and a second did not
have a specimen submitted for culture. Because this was not a
treatment study, all participants received other intravenous anti-
biotics to treat their acute pulmonary exacerbation, with the most
common regimens including a beta-lactam, typically ceftazidime
or meropenem, plus an aminoglycoside.
Ceftolozane pharmacokinetics. A total of 111 ceftolozane
concentrations were available for model development (Fig. 1). A
two-compartment model fit the data best, as determined by a
smaller AIC score of 700.90, versus 849.28 for the one-compart-
mentmodel. Among all tested covariates, onlyCLCR (ml/min)was
significantly associated with ceftolozane clearance (r 0.71, P
0.001). The final model produced an AIC of 699.11 and estimated
clearance as a ratio of CLCR [CL (liters/h)CLi
 (CLsCLCR)],
where CLi represents the intercept estimate (i.e., nonrenal clear-
ance) and CLs represents the slope estimate (i.e., proportion of
CLCR including a unit correction responsible for renal clearance).
The final parameter estimates from the populationmodel are pre-
sented in Table 2. The final estimate for	was 1.54, indicating little
environmental variability. The observed versus population-pre-
dicted ceftolozane concentration and the observed versus individ-
ual-predicted ceftolozane concentration are provided in Fig. 2.
Tazobactampharmacokinetics. For tazobactam, a total of 106
concentrations were available for model development. Notably,
36 (34%) of the tazobactam concentrations were undetectable
(n  32) or below the limit of detection (BDL) (n  4). The
majority (81%) of these undetectable or BDL samples were
troughs, occurring at 0 h (immediately before the final dose) or
360 to 420min after the end of the infusion. Samples that resulted
in no peaks on the chromatogramwere represented as zero during
model fitting, while samples that were below the limit of detection
but resulted in a visual peak on the chromatogram were repre-
sented as the estimated concentration. Modeling was performed
with and without these BDL concentration data; no differences in
parameter estimates were found, so all data were used to develop
the final model. A two-compartment model fit the data best, as
determined by a smaller AIC score of 383.50, versus 401.94 for the
one-compartment model. The final parameter estimates from the
population model are presented in Table 3. The final estimate for
	was 5.53. The observed versus population-predicted tazobactam
concentration and the observed versus individual-predicted tazo-
bactam concentration are provided in Fig. 3.
Monte Carlo simulation.The PTA results for 1.5 g and 3 g q8h
as 60-min infusions are displayed in Fig. 4. The optimal PTA was
achieved for the 1.5-g dose at fTMIC targets of 39%, 60%, and
100% for MICs of 8, 4, and 2 g/ml, respectively. The optimal
PTA was achieved for the 3-g dose at fTMIC targets of 39%,
60%, and 100% for MICs of16, 8, and 4 g/ml, respectively.
Safety and tolerability. Ceftolozane-tazobactam was well tol-
erated in this study, with only one participant discontinuing ther-
apy secondary to an allergic reaction after the first dose. Adverse
eventswere reported in 6 participants and included chest tightness
and tongue swelling (n 1), erythema in upper extremities (n
TABLE 1 Baseline characteristics of 20 CF adults
Characteristic Value (n 20)
Age (yr), mean SD (range) 25.4 9.7 (18–53)
Wt (kg), mean SD (range) 53.2 8.2 (39.8–69.4)
Height (cm), mean SD (range) 161.8 8.29 (149.7–175.3)
Male gender, no. (%) 6 (30)
Body mass index (kg/m2), mean SD (range) 20.4 3.32 (15.3–25.3)
Fat free mass (kg), mean SD (range) 38.4 6.6 (29.5–53.5)
Lean body wt (kg), mean SD (range) 41.8 5.6 (33.5–55.8)
Baseline CLCR
a (ml/min), mean SD (range) 117.7 33.1 (62–197)
a Creatinine clearance calculated via the Cockcroft-Gault equation using actual body
weight.
FIG 1 Observed ceftolozane concentrations in 20 CF adults.
TABLE 2 Final ceftolozane population pharmacokinetic parameter
estimates for 20 adults with CF
Pharmacokinetic parametera Mean SD Median
Observed
Vc (liters) 7.51 2.05 8.11
CLi (liters/h) 2.00 0.85 2.21
CLs (liters/h) 0.02 0.01 0.02
Kcp (h
1) 0.87 1.98 0.23
Kpc (h
1) 0.66 0.46 0.48
Calculated
CL (liters/h) 4.76 1.13 4.84
t1/2 (h) 2.87 0.97 2.91
a Vc, volume of central compartment; CLi and CLs, clearance intercept term and
clearance slope term, respectively, where total body clearance (CL) CLi
 (CLs
CLCR) and CLCR is creatinine clearance (ml/min) calculated with the Cockcroft-Gault
equation; Kcp and Kpc, intercompartment transfer constants; t1/2, half life.
Monogue et al.
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1), electrolyte abnormalities (n 2), vaginal itching (n 1), and
elevated liver function test results (n 1).
DISCUSSION
Ceftolozane-tazobactam has the potential to join the antibiotic
armamentarium for the treatment of acute pulmonary exacerba-
tions in cystic fibrosis patients. This antibiotic retains activity
against P. aeruginosa isolates not susceptible to other commonly
used antipseudomonal agents and has demonstrated excellent
penetration into the epithelial lining fluid of healthy volunteers (8,
20, 21). The pharmacokinetics of ceftolozane-tazobactam have
been studied in healthy volunteers, patients with renal dysfunc-
tion, and patients with active infections (5, 22). However, to our
knowledge, this is the first pharmacokinetic study of ceftolozane
and tazobactam in adults with CF during an acute pulmonary
exacerbation.
The concentration data for both ceftolozane and tazobactam
were best described by 2-compartment models. CLCR was found
to be the most significant covariate on ceftolozane clearance,
which is anticipated as ceftolozane is eliminated primarily via glo-
merular filtration (14, 23). The final equation for clearance in the
population pharmacokinetic model of ceftolozane was CL 
2.00 
 (0.02  CLCR). In contrast to the case for other patient
characteristics (e.g., body weight and height), this equation signif-
icantly improved the fit compared with the base model. These
findings suggest that there is an 10% change in ceftolozane
clearance for every 20% increase or decrease in CLCR. Similarly, a
population pharmacokinetic study including healthy volunteers
and non-CF patients observed clearance to change by 15% for
every 20% change in CLCR (22). We did not identify any direct
relationshipswith body size descriptors and ceftolozane clearance,
which is also reflective of the findings by Chandorkar and col-
leagues (22). Importantly, mean clearance estimates for our pa-
tients and adults without CF with normal kidney function were
similar (CF CL, 4.76 liters/h; non-CF CL, 5.11 liters/h) (22).
In contrast with Chandorkar and colleagues, we were not able
to identify any significant relationship between actual bodyweight
and volume of the central compartment (Vc) for ceftolozane with
linear or allometric scaling (22). Other body weight descriptors
(lean body weight, BMI, and fat free mass) were also not signifi-
cantly associated with the volume of the central compartment in
our CF population. We attribute this lack of finding to the small
range of body weights in our study population, which may have
prevented identification of a significant relationship. Despite this,
these CF patients had smaller volume of the central compartment
estimates than those without CF (CF Vc, 7.51 liters; non-CF Vc,
11.4 liters). This finding is further exemplified by greater ceftolo-
zane maximum concentrations (Cmax) achieved in this CF popu-
lation than in healthy volunteers receiving the same dose (23).
Since ceftolozane diffuses into the extracellular fluid, these differ-
ences may be attributed to the lower body weight of the 20 CF
patients studied (22, 23). These observed differences in the vol-
ume of the central compartment estimates between CF and
non-CF patients are further exaggerated when active infection is
considered. Chandorkar and colleagues (22) observed the average
Vc to be 11.4 liters in healthy volunteers but 21% to 59% higher in
FIG 2 Observed versus population-predicted (left) and maximum a posteriori probability (MAP) Bayesian individual-predicted (right) (using median param-
eter estimates) ceftolozane concentrations for the final model.
TABLE 3 Final tazobactam population pharmacokinetic parameter
estimates for 20 adults with CF
Pharmacokinetic parametera Mean SD Median
Observed
Vc (liters) 7.85 2.66 8.42
CL (liters/h) 20.51 4.41 20.13
Kcp (h
1) 1.88 1.91 0.97
Kpc (h
1) 2.49 2.29 1.52
Calculated
t1/2 (h) 2.91 2.44 3.07
a Vc, volume of central compartment; CL, clearance; Kcp and Kpc, intercompartment
transfer constants; t1/2, half life.
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infected patients with complicated urinary tract and intra-ab-
dominal infections, respectively. Given that our CF patients were
enrolled with an acute pulmonary exacerbation of their chronic
infection, this makes the differences in volumes of distribution
compared with those in non-CF infected patients (22) more pro-
found (20%). Despite these observed differences, the observed
half-life for ceftolozane (2.87  0.97 h) in these CF patients was
similar to estimates in healthy volunteers with normal kidney
function (3 h) (23).
Similar observations were apparent with tazobactam. Clear-
ance estimates in CF patients were similar to those in adults with-
out CF (CF CL, 20.5 liters/h; non-CF CL, 18.0 liters/h), while the
volumeof the central compartmentwas approximately half of that
in adults without CF (CFVc, 7.9 liters; non-CFVc, 14.2 liters) (22).
Again, this is likely associated with the low body weights of the CF
population, as tazobactam distributes mainly into extracellular
space (24). While tazobactam has been used extensively in com-
bination with piperacillin, this is the first data for tazobactam
pharmacokinetics in CF patients.
Due to the morbidity and mortality associated with acute pul-
monary infections, optimal antimicrobial treatment is prudent,
considering that approximately 70% of the adult CF population is
FIG 3 Observed versus population-predicted (left) and maximum a posteriori probability (MAP) Bayesian individual-predicted (right) (using median param-
eter estimates) tazobactam concentrations for final model.
FIG 4 Monte Carlo simulation results, showing the probability of the ceftolozane component of ceftolozane-tazobactam at 1.5 g (left) and 3 g (right) q8h as
60-min infusions achieving 39%, 60%, and 100% fTMIC in adults with CF with a mean (range) CLCR of 117.7 (62 to 197) ml/min.
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infected with P. aeruginosa (2, 25). The MIC50 and MIC90 of cef-
tolozane alone againstP. aeruginosa isolates fromCFpatients have
been reported as 0.5 and 2 g/ml, respectively (20). A similar
study in children with CF with multidrug-resistant strains dem-
onstrated higher MIC50 and MIC90 values of 2 and 8 g/ml, re-
spectively (8). The Food and Drug Administration (FDA) and the
European Committee on Antimicrobial Testing (EUCAST) cur-
rently define P. aeruginosa susceptibility to ceftolozane-tazobac-
tam as an MIC of 4/4 g/ml (26, 27). Due to high observed
concentrations, presumably because of low body weight, the stan-
dard ceftolozane-tazobactam dosing regimen, 1.5 g q8h, was still
able to obtain a PTA of 90% at MICs up to 8, 4, and 2 g/ml
using fTMIC targets of 39%, 60%, and 100%, respectively. In
contrast, the higher dose currently being studied for nosocomial
pneumonia, 3 g q8h, obtained a PTAof90%atMICs up to 16, 8,
and 4g/ml for those pharmacodynamic thresholds, respectively.
The ceftolozane fTMIC required for successful treatment of a
CF acute pulmonary exacerbation is not known; therefore, in
the absence of these data, we have settled on the human data
with cefepime and ceftazidime to guide our dosing recommen-
dations (i.e., 60% fTMIC). Considering the risk of antibiotic-
resistant bacteria, we advocate for the higher dosing regimen
for CF patients with normal kidney function until the pharma-
codynamic threshold in CF pulmonary exacerbation can be
determined (16, 19).
Ceftolozane-tazobactam at 3 g q8h was well tolerated in these
adult CF patients. Adverse effects while receiving ceftolozane-ta-
zobactam were mild, and most could be attributed to a coadmin-
istered medication. Notably, one participant did develop a type I
hypersensitivity reaction with chest tightness and throat swelling
while receiving the first dose. This participant was not noted to be
allergic to any other cephalosporins or piperacillin-tazobactam
but immediately had her infusion abated, was removed from the
study, and was treated accordingly with supportive care, with full
recovery. Electrolyte abnormalities (hypokalemia) and elevated
liver function test (alanine aminotransferase [ALT] and aspartate
transaminase [AST]) effects are reported in the ceftolozane-tazo-
bactam package insert, based on a 1.5-g dose. Participants had
these abnormalities at baseline, whichwere further exaggerated by
ceftolozane-tazobactam administration.
There are some limitations to this study. Only 20 adult CF
patients were enrolled, and most were homogenous in body size
and kidney function. We cannot, therefore, extrapolate our con-
clusions on ceftolozane pharmacokinetics using this model to
heavier CF patients or those with poor kidney function (60 ml/
min), although presumably, similar reductions in CLCR would
require dosage adjustment as per current standard prescribing
recommendations. We also did not enroll pediatric CF patients, a
very important population for whom further study of ceftolo-
zane-tazobactam pharmacokinetics is required. Finally, this study
was not designed to be a clinical trial, so no outcome data were
collected, and all participants were concurrently treated with
other antibiotics targeting their acute pulmonary exacerbation.
However, the observations in this study justify clinical assess-
ments of ceftolozane-tazobactam at an optimized dosing regimen.
In conclusion, 2 population pharmacokinetic models were de-
veloped that accurately describe ceftolozane and tazobactam
pharmacokinetics in adult CF patients with acute pulmonary ex-
acerbation and suggest some differences in mean parameter esti-
mates compared with those in adults without CF. CF patients
demonstrate similar clearance rates but smaller volumes of the
central compartment for both compounds, which could potenti-
ate higher ceftolozane-tazobactam concentrations than seen in
non-CF patients, as observed in our study. These higher concen-
trations did not affect the safety or tolerability of this dose andmay
be of benefit when treating resistant organisms as demonstrated
by the Monte Carlo simulation. These observations support fur-
ther development of ceftolozane-tazobactam for the treatment of
CF acute pulmonary exacerbation due to P. aeruginosa.
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